Naomi Laing

1.2k total citations
31 papers, 804 citations indexed

About

Naomi Laing is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Naomi Laing has authored 31 papers receiving a total of 804 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Naomi Laing's work include Estrogen and related hormone effects (4 papers), Cancer Genomics and Diagnostics (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Naomi Laing is often cited by papers focused on Estrogen and related hormone effects (4 papers), Cancer Genomics and Diagnostics (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Naomi Laing collaborates with scholars based in United States, United Kingdom and Brazil. Naomi Laing's co-authors include Kenneth D. Tew, Linda R. Barone, L A Speicher, Sulabha Ranganathan, Siqing Fu, Talia Golan, Björn Dahllöf, Gu Mi, Yung‐Jue Bang and Beryl Hartley‐Asp and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

Naomi Laing

30 papers receiving 796 citations

Peers

Naomi Laing

ONCOL

PRM

Raymond Wadlow United States

Carla Kurkjian United States

Ben Allal France

Michaela Medová Switzerland

Evangelos Bournakis Greece

Justine Y. Bruce United States

Yi‐Hung Carol Tan United States

Julia Kirshner United States

Davide Torti Italy

Raymond Wadlow United States

Naomi Laing

485 ×1.1

ONCOL

484 ×1.3

179 ×1.0

PRM

196 ×1.5

51 ×0.6

Citations per year, relative to Naomi Laing Naomi Laing (= 1×) peers Raymond Wadlow

Countries citing papers authored by Naomi Laing

Since Specialization

Citations

This map shows the geographic impact of Naomi Laing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naomi Laing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naomi Laing more than expected).

Fields of papers citing papers by Naomi Laing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naomi Laing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naomi Laing. The network helps show where Naomi Laing may publish in the future.

Co-authorship network of co-authors of Naomi Laing

This figure shows the co-authorship network connecting the top 25 collaborators of Naomi Laing. A scholar is included among the top collaborators of Naomi Laing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naomi Laing. Naomi Laing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oza, Amit M., Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, et al.. (2020). A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer. Clinical Cancer Research. 26(18). 4767–4776. 89 indexed citations

Bang, Yung‐Jue, Talia Golan, Laëtitia Dahan, et al.. (2020). Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). European Journal of Cancer. 137. 272–284. 103 indexed citations

Bang, Yung‐Jue, Talia Golan, Chia‐Chi Lin, et al.. (2019). Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).. Journal of Clinical Oncology. 37(15_suppl). 2528–2528. 26 indexed citations

Bang, Yung‐Jue, Talia Golan, Chia‐Chi Lin, et al.. (2018). Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).. Journal of Clinical Oncology. 36(4_suppl). 92–92. 19 indexed citations

Moore, Kathleen N., Karen A. Cadoo, Suzanne K. Chambers, et al.. (2017). A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Annals of Oncology. 28. v352–v353. 2 indexed citations

Golan, Talia, Chia‐Chi Lin, Siqing Fu, et al.. (2017). A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 28. iii5–iii5. 5 indexed citations

Jeselsohn, Rinath, William T. Barry, Ilenia Migliaccio, et al.. (2016). TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 22(23). 5755–5764. 20 indexed citations

Carr, T. Hedley, Robert McEwen, Brian Dougherty, et al.. (2016). Defining actionable mutations for oncology therapeutic development. Nature reviews. Cancer. 16(5). 319–329. 77 indexed citations

Malorni, Luca, Chiara Biagioni, Cristina Guarducci, et al.. (2015). AP-2gamma as a novel biomarker of endocrine resistance: Results from the TransCONFIRM study. Annals of Oncology. 26. iii15–iii15. 1 indexed citations

10.

Hird, Alexander W., Brian Aquila, M. Block, et al.. (2014). Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(7). 1820–1824. 4 indexed citations

11.

Knudsen, Steen, Thomas E. Jensen, Wiktor Mazin, et al.. (2014). Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients. PLoS ONE. 9(2). e87415–e87415. 24 indexed citations

12.

Laing, Naomi, Shenghua Wen, David C.H. Yang, et al.. (2013). Inhibition of Platelet-Derived Growth Factor Receptor α by MEDI-575 Reduces Tumor Growth and Stromal Fibroblast Content in a Model of Non-Small Cell Lung Cancer. Molecular Pharmacology. 83(6). 1247–1256. 14 indexed citations

13.

Hennessy, Edward J., Jamal Saeh, Sha Li, et al.. (2011). Discovery of aminopiperidine-based Smac mimetics as IAP antagonists. Bioorganic & Medicinal Chemistry Letters. 22(4). 1690–1694. 17 indexed citations

14.

Bornstein, Gadi Gazit, Christophe Quéva, Mohammad Tabrizi, et al.. (2009). Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational New Drugs. 28(5). 561–574. 20 indexed citations

15.

Purandare, Ashok V., Honghe Wan, Naomi Laing, et al.. (2004). Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome. Bioorganic & Medicinal Chemistry Letters. 14(18). 4701–4704. 15 indexed citations

16.

Laing, Naomi, Martin G. Belinsky, Gary D. Kruh, et al.. (1998). Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells.. PubMed. 58(7). 1332–7. 65 indexed citations

17.

Sangrajrang, Suleeporn, Philippe Denoulet, Naomi Laing, et al.. (1998). Association of Estramustine Resistance in Human Prostatic Carcinoma Cells with Modified Patterns of Tubulin Expression. Biochemical Pharmacology. 55(3). 325–331. 29 indexed citations

18.

Speicher, L A, et al.. (1994). Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells.. Molecular Pharmacology. 46(5). 866–872. 31 indexed citations

19.

Speicher, L A, Linda R. Barone, G. R. Hudes, et al.. (1994). P-glycoprotein Binding and Modulation of the Multidrug-Resistant Phenotype by Estramustine. JNCI Journal of the National Cancer Institute. 86(9). 688–694. 59 indexed citations

20.

Laing, Naomi, et al.. (1990). Phosphorus‐containing inhibitors of aspartate transcarbamoylase from Escherichia coli. FEBS Letters. 260(2). 206–208. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact